Empirical cefepime+vancomycin versus ceftazidime+vancomycin versus meropenem+vancomycin in the treatment of healthcare-associated meningitis: results of the multicenter ephesus study.
Antibiotics
Empirical therapy
Glycopeptides
Healthcare-associated meningitis
Multicenter study
Journal
BMC infectious diseases
ISSN: 1471-2334
Titre abrégé: BMC Infect Dis
Pays: England
ID NLM: 100968551
Informations de publication
Date de publication:
28 Sep 2023
28 Sep 2023
Historique:
received:
12
05
2023
accepted:
11
09
2023
medline:
2
10
2023
pubmed:
29
9
2023
entrez:
28
9
2023
Statut:
epublish
Résumé
Herein, we analyzed the efficacy of main antibiotic therapy regimens in the treatment of healthcare-associated meningitis (HCAM). This retrospective cohort study was conducted in 18 tertiary-care academic hospitals Turkey, India, Egypt and Romania. We extracted data and outcomes of all patients with post-neurosurgical meningitis cases fulfilling the study inclusion criteria and treated with empirical therapy between December 2006-September 2018. Twenty patients in the cefepime + vancomycin-(CV) group, 31 patients in the ceftazidime + vancomycin-(CFV) group, and 119 patients in the meropenem + vancomycin-(MV) group met the inclusion criteria. The MV subgroup had a significantly higher mean Glasgow Coma Score, a higher rate of admission to the intensive care unit within the previous month, and a higher rate of antibiot herapy within the previous month before the meningitis episode (p < 0.05). Microbiological success on Day 3-5, end of treatment (EOT) clinical success (80% vs. 54.8%% vs 57.9%), and overall success (EOT success followed by one-month survival without relapse or reinfection 65% vs. 51.6% vs. 45.3%), EOT all cause mortality (ACM) and day 30 ACM (15% vs. 22.6% vs. 26%) did not differ significantly (p > 0.05) among the three cohorts. No regimen was effective against carbapenem-resistant bacteria, and vancomycin resulted in an EOT clinical success rate of 60.6% in the methicillin-resistant staphylococci or ampicillin-resistant enterococci subgroup (n = 34). Our study showed no significant difference in terms of clinical success and mortality among the three treatment options. All regimens were ineffective against carbapenem-resistant bacteria. Vancomycin was unsuccessful in approximately 40% of cases involving methicillin-resistant staphylococci or ampicillin-resistant enterococci.
Sections du résumé
BACKGROUND
BACKGROUND
Herein, we analyzed the efficacy of main antibiotic therapy regimens in the treatment of healthcare-associated meningitis (HCAM).
MATERIALS/METHODS
METHODS
This retrospective cohort study was conducted in 18 tertiary-care academic hospitals Turkey, India, Egypt and Romania. We extracted data and outcomes of all patients with post-neurosurgical meningitis cases fulfilling the study inclusion criteria and treated with empirical therapy between December 2006-September 2018.
RESULTS
RESULTS
Twenty patients in the cefepime + vancomycin-(CV) group, 31 patients in the ceftazidime + vancomycin-(CFV) group, and 119 patients in the meropenem + vancomycin-(MV) group met the inclusion criteria. The MV subgroup had a significantly higher mean Glasgow Coma Score, a higher rate of admission to the intensive care unit within the previous month, and a higher rate of antibiot herapy within the previous month before the meningitis episode (p < 0.05). Microbiological success on Day 3-5, end of treatment (EOT) clinical success (80% vs. 54.8%% vs 57.9%), and overall success (EOT success followed by one-month survival without relapse or reinfection 65% vs. 51.6% vs. 45.3%), EOT all cause mortality (ACM) and day 30 ACM (15% vs. 22.6% vs. 26%) did not differ significantly (p > 0.05) among the three cohorts. No regimen was effective against carbapenem-resistant bacteria, and vancomycin resulted in an EOT clinical success rate of 60.6% in the methicillin-resistant staphylococci or ampicillin-resistant enterococci subgroup (n = 34).
CONCLUSIONS
CONCLUSIONS
Our study showed no significant difference in terms of clinical success and mortality among the three treatment options. All regimens were ineffective against carbapenem-resistant bacteria. Vancomycin was unsuccessful in approximately 40% of cases involving methicillin-resistant staphylococci or ampicillin-resistant enterococci.
Identifiants
pubmed: 37770836
doi: 10.1186/s12879-023-08596-z
pii: 10.1186/s12879-023-08596-z
pmc: PMC10540455
doi:
Substances chimiques
Vancomycin
6Q205EH1VU
Meropenem
FV9J3JU8B1
Cefepime
807PW4VQE3
Ceftazidime
9M416Z9QNR
Anti-Bacterial Agents
0
Ampicillin
7C782967RD
Types de publication
Multicenter Study
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
639Informations de copyright
© 2023. BioMed Central Ltd., part of Springer Nature.
Références
Clin Microbiol Rev. 2018 Feb 14;31(2):
pubmed: 29444952
N Engl J Med. 2010 Jan 14;362(2):146-54
pubmed: 20071704
Curr Opin Anaesthesiol. 2022 Oct 1;35(5):549-554
pubmed: 35943123
Scand J Infect Dis. 2011 Oct;43(10):757-64
pubmed: 21671825
J Infect. 2013 Aug;67(2):161-4
pubmed: 23583325
N Engl J Med. 1993 Jan 7;328(1):21-8
pubmed: 8416268
Bone Marrow Transplant. 2003 Jan;31(1):65-7
pubmed: 12621510
Neurol India. 2008 Oct-Dec;56(4):433-7
pubmed: 19127038
J Hosp Infect. 2007 May;66(1):71-8
pubmed: 17433493
Clin Infect Dis. 2017 Mar 15;64(6):e34-e65
pubmed: 28203777
J Infect Chemother. 2020 Jan;26(1):101-106
pubmed: 31445817
Turk J Med Sci. 2016 Feb 27;47(1):29-33
pubmed: 28263502
Clin Microbiol Rev. 2010 Oct;23(4):858-83
pubmed: 20930076
J Clin Neurosci. 2005 Aug;12(6):647-50
pubmed: 16023857
Int J Antimicrob Agents. 2005 May;25(5):414-8
pubmed: 15848297
Lancet. 2012 Nov 10;380(9854):1693-702
pubmed: 23141618
Am J Infect Control. 2002 May;30(3):158-64
pubmed: 11988710
Infect Drug Resist. 2022 Feb 28;15:697-721
pubmed: 35250284
Clin Microbiol Infect. 2016 May;22 Suppl 3:S37-62
pubmed: 27062097
Mikrobiyol Bul. 2017 Jul;51(3):277-285
pubmed: 28929964
Clin Infect Dis. 2004 Nov 1;39(9):1267-84
pubmed: 15494903
Expert Rev Anti Infect Ther. 2008 Aug;6(4):523-39
pubmed: 18662118
Expert Rev Anti Infect Ther. 2014 Mar;12(3):333-42
pubmed: 24512210